(firstQuint)Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies.

 This compassionate use program will consist of a Pretreatment Phase and a Treatment Phase.

 Patients with locally advanced or metastatic breast cancer who fulfill the eligibility criteria may be treated.

 Safety data will be collected, but a minimal amount of other data will also be collected.

.

 Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies@highlight

The purpose of this study is to provide eribulin to patients with advanced breast cancer who have no other treatment options and therapy is requested by an Investigator.

